Search
for
Sort by
Research 31–60 of 536
- Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
- Clinical Outcomes of Ritlecitinib in Treatment-Refractory Alopecia Areata: A Single-Center Real-World Study
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- Assessing Alopecia Areata Management in Poland: Challenges in Medical Practices and Patient Care
- Assessing Alopecia Areata Management in Poland: Challenges in Medical Practices and Patient Care
- Real World Evidence in Alopecia Areata: Current Management, Emerging Therapies and Future Challenges – A Narrative Review
- II Consensus of the Brazilian Society of Dermatology for the treatment of alopecia areata
- Comparative analysis of therapeutic outcomes in pediatric versus adult ophiasis-pattern alopecia areata: A review of treatment modalities and disease course
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- Janus Kinase Inhibitors in the Treatment of Alopecia Areata
- The Role of JAK Inhibitors in Atopic Dermatitis, Alopecia Areata, and Vitiligo: A Review article
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- Ritlecitinib: First Approval
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Janus kinase inhibitors for alopecia areata: A narrative review
- Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Janus kinase inhibitors for alopecia areata
- Pharmacotherapy of alopecia areata
- Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
- Current Trends and Emerging Paradigms in the Treatment of Alopecia Areata
- SYSTEMATIC REVIEW OF ORAL JANUS KINASE INHIBITORS IN ALOPECIA AREATA: INSIGHTS FROM 2020 TO 2025 STUDIES